Stuart Essig is managing partner of his family office, Prettybrook Partners, LLC. He is chairman of Integra LifeSciences Holdings Corporation (NASDAQ: IART), where he served as the company’s chief executive officer from 1997 to 2012, building Integra into a global surgical products leader. During Stuart’s 20-year tenure with the company, Integra has grown revenues from $15 million to almost $1.5 billion and its market capitalization from approximately $100 million to a levered valuation of more than $6 billion. He is chairman of Breg, Inc. and director of IDEXX Laboratories (NASDAQ: IDXX), SeaSpine, Inc. (NASDAQ:SPNE) and Owens & Minor, Inc. (NYSE: OMI). Previously, Stuart served on the board of St. Jude Medical, Inc. (NYSE: STJ) from 1999-2017 prior to its sale to Abbott Corporation. He also served on the boards of Zimmer Holdings, Inc. (NYSE: ZMH) from 2005-2008 and Vital Signs, Inc. (NASDAQ:VITL) from 1998-2002. He also served on the executive, nominating and governance committees, and as a treasurer for AdvaMed. Prior to Integra, Stuart was a managing director in mergers and acquisitions for the Goldman Sachs Group, Inc., specializing in the medical device, pharmaceutical and biotechnology sectors. After earning his undergraduate degree from Princeton University, Stuart earned a master’s in business administration and doctorate in financial economics from the University of Chicago.